Last checked at 
(For faster updates on individual market-movers, Eikon usersplease use search string "STXBZ US"; for the Day Aheadnewsletter, http://link.reuters.com/mex49s; for the Morning NewsCall newsletter, http://link.reuters.com/nex49s)U.S. stocks opened higher on Monday following a strong rally inChinese stock markets and ahead of a string of domestic economicdata. The Dow Jones industrial average was up 0.11percent at 18,031.36, the S&P 500 was down 0.02 percentat 2,106.94 and the Nasdaq Composite was up 26.03points, or 0.51 percent, to 5,096.06.
** ALTERA CORP, $51.81, +6.06 pct
** INTEL CORP, $34.2901, -0.49 pct
Intel agreed to buy Altera for $16.7 billion as the world'sbiggest chipmaker seeks to make up for slowing demand from thePC industry by expanding its line-up of higher-margin chips usedin data centers. The offer of $54 per share in cash is a 10.5percent premium to Altera's Friday close.
** MOLYCORP INC, $0.4634, -12.58 pct
The miner said it missed a $32.5 million interest payment onits senior secured notes.
** ONCOTHYREON INC, $4, +16.96 pct
** VBL THERAPEUTICS, $8.1499, +1.24 pct
** EXELIXIS INC, $3.37, +6.98 pct
** IMMUNOGEN INC, $13.844, +54.16 pct
** IMMUNOMEDICS INC, $4.013, +3.96 pct
** IGNYTA INC, $11.7601, +30.96 pct
** CELSION CORP, $2.52, +2.02 pct
The cancer drug makers presented data at the AmericanSociety of Clinical Oncology.
** CTI BIOPHARMA CORP, $2.286, +17.84 pct
The drug developer said patients given its blood cancer drugshowed improvement in key disease symptoms compared with thosegiven a standard of care in a late-stage study.
** ATYR PHARMA INC, $23.44, +2.40 pct
BMO started coverage of the drugmaker's stock with an"outperform" rating and a price target of $42, while JP Morganstarted with an "overweight" rating and a $44 price target.
** ALPHA NATURAL RESOURCES INC, $0.5049, +1.57 pct
** ARCH COAL INC, $0.5004, +2.12 pct
** CLOUD PEAK ENERGY INC, $5.39, -6.59 pct
Goldman Sachs upgraded Alpha Natural to "neutral" from"sell", saying concerns hurting the coal miner has alreadyreflected on its stock. The brokerage assumed coverage of ArchCoal with "neutral" and cut its rating on Cloud Peak to "sell"from "neutral".
** MOLYCORP INC, $0.4634, -12.58 pct
The rare earth miner is expected to announce on Monday thatit would skip a $32.5 million loan payment, which might resultin bankruptcy filing before the end of June, the Wall StreetJournal reported.
** OM GROUP INC, $33.9, +27.73 pct
Private equity firm Apollo Global Management LLC will buy the industrial magnet and battery maker for about $1.03billion, or $34 per share - a premium of 28 percent to itsFriday close.
** CELLDEX THERAPEUTICS INC, $27.3066, -5.42 pct
Adding an experimental Celldex Therapeutics vaccine thatenlists the immune system to fight cancer to standard therapyhelped patients with the deadliest type of brain cancer livelonger, according to data from a mid-stage trial presented onSunday.
** GENERAL ELECTRIC CO, $27.18, -0.33 pct
The U.S. conglomerate has launched the sales process for aroughly $40 billion portion of its U.S. commercial lendingassets as a part of its broad retreat from its financebusinesses, sources familiar with the situation said on Sunday.
** MIRATI THERAPEUTICS INC, $27.31, -25.50 pct
Brean Capital said that the most noteworthy efficacy ofcompany's lung cancer drug in early-stage study observed in justthree of 25 patients. Brean downgraded the stock to "hold",becoming the first of five brokerages to not rate the stock"buy".
** COCA-COLA CO, $41.25, +0.71 pct
BMO raised the world's largest beverage maker's stock to"outperform" from "market perform" and price target to $48 from$44.
** PFIZER INC, $34.7, -0.14 pct
A Phase III trial of the drugmaker's Ibrance showed that, incombination with hormone therapy, the drug more than doubled theduration of disease control for women with the most common typeof breast cancer.
** PRANA BIOTECHNOLOGY LTD, $1.48, +8.03 pct
The European Commission granted the Australian company's Huntington's disease treatment "orphan" drug status,which give the drug a 10-year market exclusivity and fundedresearch grants among other benefits.
** CELLADON CORP, $2.481, +7.40 pct
The troubled drug developer said it was seeking anacquisition or a partnership after its heart drug failed in keymid-stage trial. The company also replaced its CEO with its CFO.
** MICROSOFT CORP, $46.84, -0.04 pct
The software company said on Monday its new Windows 10operating system would be available worldwide on July 29 as afree upgrade for users of the most recent versions of Windows.
** JOHNSON & JOHNSON, $100.34, +0.20 pct
An experimental biotech drug being developed by the companymay offer hope to multiple myeloma patients who have run out ofoptions, according to data from a mid-stage study released at acancer meeting on Saturday.
** STIFEL FINANCIAL CORP, $54.46, +2.25 pct
The investment bank is in advanced talks to acquire BarclaysPlc's U.S wealth management unit, according to threepeople familiar with the situation.
** NVIDIA CORP, $22.32, +0.86 pct
The chipmaker said it expected cloud computing revenue tohit $1 billion in the next two to three years as demand for bigdata analysis drives growth in graphics chips.
** CYPRESS SEMICONDUCTOR CORP, $13.73, +0.00 pct
** INTEGRATED SILICON SOLUTION INC, $20.73, +1.02pct
Cypress raised its offer to buy ISSI to $20.25 per share,beating Uphill Investment Co's increased offer. ISSI said itwould hold talks with Cypress.
** WALT DISNEY CO, $110.89, +0.47 pct
The media company and theme park operator's shares couldclimb 50 percent over the next three years on its uncannyability to generate profits from its businesses includingmovies, merchandise and parks and cruise lines, Barron's said inits latest edition published on Sunday.
** BRISTOL-MYERS SQUIBB, $66.97, +3.67 pct
The company said the U.S. FDA accepted a marketingapplication for a combination of its cancer drugs Opdivo andYervoy to treat melanoma as a first-line treatment.
** ENTERPRISE PRODUCTS PARTNERS LP, $32.3, -0.37 pct
** PIONEER NATURAL RESOURCES CO, $149.02, +0.81 pct
The pipeline company Enterprise Products Partners said itwould buy member interests in EFS Midstream LLC from affiliatesof Pioneer Natural Resources Co and Reliance Industries Ltd for $2.15 billion. (Compiled by Abhirup Roy in Bengaluru)
